Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
113.84
-0.88 (-0.77%)
Feb 21, 2025, 4:00 PM EST - Market closed
Revvity Revenue
In the year 2024, Revvity had annual revenue of $2.76B with 0.16% growth. Revvity had revenue of $729.37M in the quarter ending December 29, 2024, with 4.81% growth.
Revenue (ttm)
$2.76B
Revenue Growth
+0.16%
P/S Ratio
5.08
Revenue / Employee
$239,567
Employees
11,500
Market Cap
13.85B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 2.76B | 4.46M | 0.16% |
Dec 31, 2023 | 2.75B | -561.25M | -16.95% |
Jan 1, 2023 | 3.31B | -515.99M | -13.48% |
Jan 2, 2022 | 3.83B | 1.16B | 43.73% |
Jan 3, 2021 | 2.66B | -220.44M | -7.64% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RVTY News
- 1 day ago - Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group - Business Wire
- 1 day ago - Revvity to Present at Upcoming Investor Conferences - Business Wire
- 21 days ago - Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending - Reuters
- 21 days ago - Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024 - Business Wire
- 4 weeks ago - Revvity Board Declares Quarterly Dividend - Business Wire
- 4 weeks ago - Revvity Ignites Scientific Breakthroughs at SLAS2025 - Business Wire
- 5 weeks ago - Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing - Business Wire